Independent directory Public ClinicalTrials.gov records United States
Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 9:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 2,515 matching trials from the local directory fallback.
Active, not recruiting Phase 3 Interventional

Breast Cancer WEight Loss Study (BWEL Study)

NCT02750826
Conditions
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Synchronous Bilateral Breast Carcinoma
Interventions
Health Education Program, Weight Loss Intervention
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
3,177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1464
States / cities
Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 921 more
Conditions
Advanced or Metastatic Solid Tumors, Brain Neoplasms, Differentiated Thyroid Cancer, Glioma, HGG, High Grade Glioma, LGG, Low Grade Glioma, Malignant Neoplasms, Melanoma, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, Thyroid Cancer
Interventions
PF-07799544, PF-07799933
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Rogers, Arkansas + 22 more
Conditions
Advanced Colorectal Cancer (Part 1), Glioma, Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer
Interventions
PF-07799933, binimetinib, cetuximab, fluorouracil, leucovorin, midazolam, oxaliplatin
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
31
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more
Conditions
Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma, T Lymphoblastic Lymphoma
Interventions
AKR1C3-activated Prodrug AST-3424, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
12 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
163
States / cities
Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 94 more
Conditions
Cardiovascular Disease
Interventions
Cagrilintide, Placebo, Semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years and older
Enrollment
7,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
119
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 103 more
Active, not recruiting Phase 4 Interventional

Corticosteroid Meniscectomy Randomized Trial

NCT04641351
Conditions
Meniscus Tear, Meniscus; Degeneration, Osteoarthritis, Knee, Synovitis
Interventions
Zilretta Injectable Product or Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
M281, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
29
States / cities
Fountain Valley, California • Los Angeles, California • Riverside, California + 24 more
Conditions
Anterior Cruciate Ligament Tear
Interventions
ACL Reconstruction (Bone Patellar Tendon Bone Graft), Bridge Enhanced ACL Restoration (BEAR)
Procedure · Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Boulder, Colorado • Bloomington, Minnesota • Cleveland, Ohio + 3 more
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Early Highly Effective Therapies Group, Escalation Therapies Group
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more
Conditions
Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
Axillary Lymph Node Dissection (ALND), Axillary Radiation Therapy, Nodal Radiation Therapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
2,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
1228
States / cities
Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 730 more
Conditions
Eosinophilic Esophagitis
Interventions
Budesonide
Drug
Lead sponsor
Dr. Falk Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
20
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 17 more
Conditions
Tricuspid Regurgitation, Tricuspid Valve Disease
Interventions
TricValve® Transcatheter Bicaval Valve System
Device
Lead sponsor
P+F Products + Features USA Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 31 more
Conditions
Persistent Atrial Fibrillation
Interventions
Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone, FARAPULSE™ Pulsed Field Ablation (PFA) System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 38 more
Active, not recruiting Not applicable Interventional

Project 3: ACHIEVE- CHD

NCT05918380
Conditions
Coronary Heart Disease
Interventions
CINEMA, PAL2
Other · Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Cyclophosphamide, Fludarabine Phosphate, Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Quality-of-Life Assessment, Rituximab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
781
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 509 more
Conditions
Breast Cancer
Interventions
AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, pegfilgrastim
Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
3,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
539
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 369 more
Conditions
Multiple Myeloma
Interventions
Bortezomib, Carfilzomib, Dexamethasone, Elotuzumab, Etentamig, Pomalidomide, Selinexor
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
AR-14034 SR implant, AR-14034 SR implant higher dose, AR-14034 SR implant lower dose, Aflibercept Injection, Sham procedure
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
42
States / cities
Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more
Active, not recruiting Not applicable Interventional

The BD Liverty™ TIPS Stent Graft Study

NCT05711316
Conditions
Portal Hypertension, TIPS
Interventions
BD Liverty™ TIPS Stent Graft
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 12 more
Conditions
Advanced Solid Tumor, Breast Neoplasms, Cancer, Lung Cancer, Metastatic Solid Tumor, Neuroendocrine Carcinoma, Neuroendocrine Tumors, RB1 Gene Mutation, Refractory Solid Tumor, Triple Negative Breast Cancer
Interventions
CID-078 Monotherapy
Drug
Lead sponsor
Circle Pharma
Industry
Eligibility
12 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 7 more
Conditions
Non-obstructive Hypertrophic Cardiomyopathy, Obstructive Cardiomyopathy, Hypertrophic
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 28 more
Conditions
Melanoma
Interventions
Nivolumab + Relatlimab, rHuPH20
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 12 more
Conditions
Non-small Cell Lung Cancer
Interventions
DS-1062a, Docetaxel
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Chandler, Arizona • Anaheim, California • Glendale, California + 28 more
Conditions
Alzheimer Disease
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
185
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 146 more